Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  

What's New at The Body

HIV/AIDS News You Can Use

February 26, 2003

More Highlights From the 2003 Retrovirus Conference

We know that women are at greater risk for developing bone problems than men, but could HIV infection or HAART make these problems worse? Dr. Andy Pavia reports on the latest research into bone disorders among HIV-positive women.

Once-daily ddI (didanosine, Videx EC) can be taken with tenofovir (Viread) at the same time with a light meal, provided the dose of ddI is reduced from 400 mg to 250 mg, researchers say. Dr. Edwin DeJesus has the details.

Tipranavir is one of several HIV drugs in the works that researchers hope will provide new treatment options to people who are resistant to many of the meds currently on the U.S. market. Dr. David Wohl reports on the latest tipranavir research.

Browse through the rest of The Body's Retrovirus coverage by visiting this page!

Other Sources Cover Retrovirus 2003

Since the Retrovirus conference was so massive, no single organization could possibly cover the entire thing. We'll post everything we can find about the conference, though: Here's an overview of new antiretrovirals from well-known treatment advocate Jules Levin.

You'll continue to see lots of news from this conference coming from a wide range of sources. Visit our "Conference News From Other Sources" page to stay on top of it all!

Who Will Pay for Your T-20?

$20,000 per year -- that's how much it'll cost European health plans to provide HIV-positive patients with twice-daily injections of T-20 (enfuvirtide, Fuzeon). The new HIV drug, which is aimed at people whose other HIV drug regimens have failed, could be approved for use in the U.S. as early as March. The question is: Will Medicaid, ADAP and health insurance companies balk at paying the bill?

Another Disappointment on the AIDS Vaccine Front

The first HIV vaccine tested in a large at-risk population has proven to be largely ineffective, but there's an interesting catch: The vaccine appeared to have some protective effect within a small group of non-Hispanic minorities.

New HIV Drugs in Old Drug Classes

Although T-20 and other so-called "entry inhibitors" are part of an exciting new family of HIV drugs, there are many drugs in development that improve on drug families we're already familiar with -- protease inhibitors, NRTIs and NNRTIs. ACRIA provides a rundown.

Which Is Better: Once-a-Day or Twice-a-Day HIV Meds?

Once-a-day drugs: Sure, they seem easier, but should everybody choose them over two- or three-times-a-day drugs? ACRIA takes a closer look.

Easing Lipodystrophy in Women

Doctors still aren't sure how lipodystrophy can be treated, but there are some steps women can take to lessen the symptoms. ACRIA's "Treatment Issues for Women" guide provides some tips.

"Salvaging" Your HIV Therapy

Doctors call it "salvage" therapy; treatment advocates call it "rescue" therapy -- it's what you do when most of the available HIV drugs no longer work against the virus in your body. For an in-depth look at why HIV treatments fail and how "salvage" therapy works, read this article.

Prostate Cancer a Greater Concern in Black Men

It may be especially hard for doctors to diagnose prostate cancer early in HIV-positive black men, a recent study found. As a result, black men with HIV who are over 40 should be extra diligent about getting screened for prostate cancer.

A Gay Native American's Life With HIV

Johnny Changingwolf, a gay HIV-positive half-Apache, half-Navajo, was a man who "walked between worlds." Read the story of how art therapy brought Johnny back from life's precipice.

Government Backs Off Gay Safe-Sex Program

U.S. health officials have given the thumbs-up to controversial workshops run by the Stop AIDS Project in San Francisco. A Republican Congressman had accused them of promoting sexual activity in violation of government guidelines; an earlier government report called the workshops "obscene."

Why Prison Authorities Don't Like HIV Treatment Educators

Prison services coordinator Hugo Mendez talks about the fine line an HIV treatment educator must walk in the U.S. prison system: "Because there is the potential for informed prisoners to advocate for specific (and often expensive) medications by name, administrators look at education as a hindrance in the system."

Organ Transplants Safe in People With HIV

Now that HIVers are living longer than ever, the number of organ transplants in people with HIV is on the rise. A recent study looked at the risks of kidney and liver transplants in HIVers, and found encouraging results.

Kaletra: The Toughest PI There Is

Kaletra (a combination of two drugs, lopinavir and ritonavir) is widely considered the most powerful protease inhibitor on the market today. To learn more about it, click here.

Interleukin-2, What Are You?

It's the experimental HIV treatment that just won't go away: Project Inform updates us on the trials and tribulations of Interleukin-2, an immune-based therapy with a very rocky history.

Web Highlights

A Selection of the Top HIV/AIDS Stories From Across the Internet:

Lessons From Uganda's AIDS Success Story
Six percent of the population has HIV, a much lower percentage than in most of sub-Saharan Africa
From The Daily News (Harare) (February 26, 2003)

Nevirapine Studied as Pre-Exposure Prophylaxis for HIV
Early trials suggest a low dose of the drug may be safely used in HIV prevention
From AIDS Map (February 25, 2003)

Three Times as Many People Living With HIV/AIDS in Middle East, West Asia Than Three Years Ago, WHO Reports
Since 1999, the number of HIV-positive people in these areas has risen from 220,000 to 700,000
From Kaiser Daily HIV/AIDS Report (February 24, 2003)

Baby Love
More often than ever before, women with HIV in the U.S. can now have HIV-negative babies, peace of mind during pregnancy and hope for a long, healthy motherhood
From POZ Magazine (December 2002)

  
Previous Update | Next Update
Back to The Body's HIV/AIDS News Updates main page